Celsis History
Celsis International Ltd., a leading provider of life science products and laboratory services to the pharmaceutical and consumer products industries, operated worldwide through its three areas of business: Rapid Detection Systems, Analytical Laboratory Services and In Vitro ADME-Tox products. Each Celsis division delivered substantial time and cost savings to customers in addition to ensuring product quality and safety for consumers.
Company Milestones
-
2015
-
Celsis Rapid Detection acquired by Charles River Laboratories
- 2013 -
- 2011 -
-
2009
-
Private equity investors led by Christopher Mills takes Celsis private, forming Celsis International Ltd. and retaining Jay LeCoque as CEO
- 2006 -
-
2003
-
Celsis awarded Best Performing Share on TechMark Mediscience Index
-
2001
-
Celsis acquires Concell, founded by Veikko Tarkkanen and founder of Lumac, one of the originators of ATP microbial screening applications
-
2000
-
Jay LeCoque named CEO and Christian Madrolle named Finance Director
-
1999
-
Jack Rowell, OBE, Non-Executive Chairman of Celsis named Interim CEO
-
1996
-
Celsis acquires Lumac, leading manufacturer of ATP based microbial screening solutions for industry
-
1995
-
Jay LeCoque joins Celsis as a Director of Global Business Development
-
1994
-
Arthur Holden named CEO
-
1993
-
Celsis International plc IPO on London Stock Exchange
-
1992
-
Celsis founded in Cambridge, England by Sir Christopher Evans
Awards
-
2016
-
Jay LeCoque awarded CEO of the Year for the Biotech Industry by Acquisition International
-
2010
, 2011
, 2013
and 2014
-
Celsis named to Supply & Demand Chain Executive Top 100 list
-
2009
-
Manufacturing Business Technology’s New Product Innovation Award
-
2008
-
Frost & Sullivan Best Practice Award for Rapid Detection in the Pharmaceutical Industry
- 2003 -
